Vol 9, No 3 (2013)

Cover Page

DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER

IDENTIFICATION OF PROGNOSTIC FACTORS OF THE EFFICIENCY OF BEVACIZUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL-CELL CANCER

Alekseyev B.Y., Kalpinsky A.S., Nyushko K.M., Klimenko A.A., Anzhiganova Y.V., Varlamov S.A., Bichurina S.A., Vasilyev L.A., Arkhipov A.V., Gurina L.I., Leonov O.V.

Abstract

Cancer Urology. 2013;9(3):17-23
pages 17-23 views

THE FIRST RESULTS OF TARGETED THERAPY FOR KIDNEY CANCER IN MOSCOW

Shirokorad V.I., Makhson A.N., Borisov V.I., Minakova L.R., Popov M.I., Shchupak M.Y., Kirdakova N.V., Mishugin S.V., Maturov M.R., Vinogradsky A.G., Shikhov S.D., Gaidamaka E.V., Apolskaya N.A., Shushakov M., Babaev E.R., Vorontsova A.A., Ivanov A.M., Amosov F.R., Kolesnikov G.P.

Abstract

The paper provides the first interim analysis of a database including information on 427 metastatic kidney cancer patients receiving targeted therapy in the cancer facilities of the Moscow Healthcare Department. It shows a comparative analysis of the periods of first-line targeted therapy with different drugs until progression is established.
Cancer Urology. 2013;9(3):24-29
pages 24-29 views

USE OF A COMBINATION OF АVASTIN AND LOW-DOSE INTERFERON- α IN THE FIRST-LINE TREATMENT OF METASTATIC RENAL-CELL CANCER

Kalpinsky A.S., Alekseyev B.Y., Kaprin A.D.

Abstract

Cancer Urology. 2013;9(3):30-36
pages 30-36 views

IMMUNOTHERAPY FOR METASTATIC KIDNEY CANCER: ITS ROLE AT THE PRESENT STAGE AND PROSPECTS FOR CLINICAL APPLICATION

Nosov D.A., Voroshilova E.A., Sayapina M.S.

Abstract

With the clinical introduction of targeted drugs, the results of therapy in patients with metastatic renal-cell carcinoma (mRCC) of all prognostic groups as witnessed by the data of randomized trials. Nevertheless, there is a group of favorable prognosis patients (MSKCC) that may use first-line immunotherapy equally with a targeted approach without apparently affecting overall survival. As a rule, these are the patients who have no symptoms of the disease with the primary tumor being removed and the disease is being minimally disseminated. At the same time, how long very rare (1 %) complete remissions achieved by targeted drugs last, whether they can transformed into complete recovery, and how this may be observed in 3–4 % of cases when immune therapeutic options are used in favorable prognosis patients remain to be investigated. Due to the fact that nonspecific therapy involving cytokines fails to overcome fully the phenomenon of immunological tumor tolerance and has limited antitumor activity, the clinical trials are actively studying the efficiency of more specific immunotherapeutic approaches, such as anti-CTLA-4, anti-PD1 monoclonal antibodies, as well as different vaccination types.

Thus, there is an opportunity to make the immunotherapeutic approach molecular targeted and to integrate it into a drug treatment algorithm for patients with mRCC. Accordingly, the priority for additional clinical trials is to identify predictive markers of response (or resistance) to immunotherapy that can rationalize and individualize this therapeutic approach.

Cancer Urology. 2013;9(3):37-42
pages 37-42 views

REVIEW

SATURATION BIOPSY OF THE PROSTATE (REVIEW)

Sadchenko A.V., Govorov A.V., Pushkar D.Y., Vasiliev A.O.

Abstract

Prostate biopsy is the principal method of diagnois of prostate cancer, allowing to start the adequate treatment. The tactics of the patients, which have negative initial biopsy, is a subject of discussion. Saturation biopsy is a “gold standard„ of diagnostics of PCA with repeat biopsy. Saturation biopsy of the prostate is not a primary procedure, usually apply in patients with negative biopsies in anamnesis, patients with multifocal PIN and ASAP. Saturation biopsy allows to more precisely predict the volume and degree of malignancy of PCA, that can be used for planning tactics of active surveillance and focal therapy.

Cancer Urology. 2013;9(3):70-75
pages 70-75 views

ПРИМЕНЕНИЕ 1-, 3- И 6-МЕСЯЧНЫХ ЛЕКАРСТВЕННЫХ ДЕПО-ФОРМ ЛЕЙПРОРЕЛИНА АЦЕТАТА В ГОРМОНАЛЬНОЙ ТЕРАПИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ В 9 ЕВРОПЕЙСКИХ СТРАНАХ: ОБЗОР ДОКАЗАТЕЛЬСТВ И ЭКОНОМИЧЕСКАЯ ОЦЕНКА

Wex J., Sidhu M., Odeyemi I., Abou-Setta A., Retsa P., Tombal B.

Abstract

Применение 1-, 3- и 6-месячных лекарственных депо-форм лейпрорелина ацетата в гормональной терапии рака предстательной железы в 9 европейских странах: обзор доказательств и экономическая оценка.

Cancer Urology. 2013;9(3):76-89
pages 76-89 views

PROSTATE CANCER

CONTINENT RADICAL PROSTATECTOMY

Sernyak Y.P., Fukszon А.S., Roshchin Y.V., Frolov A.S.

Abstract

Objective: to evaluate the impact of dissection of the dorsal venous complex without pre-ligation, suturing, or coagulation during radical prostatectomy (RPE) in patients with localized prostate cancer (PC) on the quality of surgery and the function of urinary retention.

Subjects and methods. The data of 42 patients who had undergone posterior and anterior anatomical repair and vesicourethral anastomosis using a V-lock suture after prostatectomy were analyzed. All the patients were divided into 2 groups. Group 1 consisted of 22 patients in whom the dorsal venous complex was closed using a 3-0 vicryl suture before urethral dissection. Group 2 included 20 patients in whom the urethra was dissected without suturing the venous complex.

Results. In group 1, complete urinary retention after catheter removal was noted in 9 (40.9 %) and 15 (68 %) patients within 24 hours and after 3 months, respectively. Following 12 months, two (9 %) patients were observed to have partial mild urinary incontinence (as many as 2 pads per day). Group 2 patients showed complete urinary retention in 17 (85 %) cases on the first day after catheter removal; all the patients retained urine 3 months later.

Conclusion. In patients with localized PC, dissection of the dorsal venous complex without presuturing during laparoscopic RPE exerts a considerable impact on the preservation of urinary retention, namely 45% more of the patients reported complete urinary retention in early periods and 10 % more did this in later periods. At the same time, there was no statistically significant increase in intraoperative blood loss (p > 0.05), the number of positive edges, or biochemical recurrences.

Cancer Urology. 2013;9(3):43-47
pages 43-47 views

RADICAL PROSTATECTOMY FOR PATIENTS WITH CLINICALLY LOCALIZED AND LOCALLY ADVANCED PROSTATE CANCER: THE REMOTE RESULTS OF TREATEMENT

Grygorenko V.N., Danilets R.O., Mezheritskiy S.N.

Abstract

Cancer Urology. 2013;9(3):48-54
pages 48-54 views

THE LONG-TERM ONCOLOGICAL RESULTS OF RADICAL PROSTATECTOMY IN PATIENTS WITH A MAXIMUM FOLLOW-UP OF UP TO 15 YEARS, WHO MEET THE ERSPC (PRIAS) CRITERIA FOR ACTIVE SURVEILLANCE

Veliev E.I., Loran O.B., Sokolov E.A.

Abstract

No consensus on how to select patients is one of the factors restricting the wide acceptance of active surveillance (AS). The frequency of unfavorable histological findings and long-term overall and relapse-free survival rates were studied in 152 patients who met the ERSPC [European Randomized Study of Screening for Prostate Cancer] (PRIAS) criteria for AS and had undergone retropubic prostatectomy (RPE) in the period 1997 to 2010. Negative histological characteristics were found in more than 10 % of the patients, with the median postoperative followup of 67 months biochemical recurrence developed in 3 (2 %) patients. Five- and ten-year relapse-free survival rates were 97 and 88.2 %, respectively. Histological and long-term oncological results after RPE are suboptimal in the patients meeting the PRIAS criteria. There is a need for additional studies of the safety and efficiency of AS under conditions of Russian public health.

Cancer Urology. 2013;9(3):55-58
pages 55-58 views

THE SHORT-TERM PERFORMANCE RESULTS OF PROSTATE ADENOCARCINOMA MULTIMODAL TREATMENT IN NOVOSIBIRSK REGION

Kunin I.S., Korotkov E.A., Aidagulova S.V., Seryapina Y.V., Anikeeva О.Y., Vorobjeva Т.G., Bedniy I.V., Narov Y.E., Ivaninskiy О.I., Marinkin I.О.

Abstract

The short-term performance criteria (PSA blood level and prostate volume) were analyzed concerning the complex (hormonal and radiation) treatment of 57 patients with prostate adenocarcinoma, stratified into three disease progression risk groups. Two treatment regimens were differed in the duration of neoadjuvant hormone therapy: 9 or 32 ± 13 months in combination with external beam radiation therapy with a total dose 76–80 Gy. Statistical analysis of the multimodal treatment efficiency criteria of patients with high risk of prostate adenocarcinoma showed the best result (significant decrease of PSA blood level) using a single 9-month course of hormone therapy and subsequent external beam radiation therapy. The prostate volume indicator in the applicable mode of radiation therapy has mixed dynamics, and requires further study as a multimodal treatment effectiveness criterion.

Cancer Urology. 2013;9(3):59-63
pages 59-63 views

PROGNOSTIC FACTORS OF BIOCHEMICAL RELAPSE FREE SURVIVAL FOLLOWING SALVAGE RADIOTHERAPY IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

Demeshko P.D., Sukonko O.G., Krasny S.A., Suslova V.A.

Abstract

Purpose. To evaluate influence of clinical, biochemical and histological factors to biochemical relapse free survival (BRFS) following salvage radiotherapy (RT) in men with biochemical recurrence after radical prostatectomy.

Material and methods. 77 patients with newly diagnosed biochemical recurrence (BR) after RPE were included into retrospective study. All of them underwent local salvage RT. Сlinical variables (age, serum prostate-specific antigen [PSA] level and PSA kinetics, time RPE-BR, Gleason grade, stage after RPE and clinical findings) were evaluated using Cox proportional hazards regression analysis.

Results. The median, 1- and 3-year BRFS were 19,9 months, 63,8 ± 6,5 % and 24,7 ± 8,5 % respectively. Significant variables in the multivariable model were age, PSA level before RT, prostatectomy T3b stage, PSA doubling time and positive digital rectal examination findings (p < 0,05). Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in counseling men regarding the timing of administration of adjuvant therapies.

Cancer Urology. 2013;9(3):64-69
pages 64-69 views

CLINICAL CASE

POSTHERAPEUTICAL MATURE RESIDUAL TERATOMA INTRAHЕАRT INTRACARDIAC METASTASIS NON-SEMINOMATOUS GERM CELL TUMOR STAGE III (PT3N2M1S1). INTEGRATION OF CLINICAL ONCOLOGY AND CARDIOSURGERY: CASE REPORT AND REVIEW LITERATURE

Almyashev A.Z., Ipatenko V.T., Tirkin G.F.

Abstract

We report a case of a 45-year-old man with testicular cancer. The patient received radical orchiectomy. After the diagnosis of nonseminomatous testicular cancer (embryonic carcinoma), he was treated successfully with 4 cycles of systemic chemotherapy. After 3 months admitted with respiratory distress and found to have mass in right ventriсle of the heart. This is a rare case that presented with metastatic testicular cancer involving heart and causing symptomatic obstruction of blood flow tract.

Cancer Urology. 2013;9(3):90-95
pages 90-95 views

PROSTATECTOMY FOR METASTATIC PROSTATE CANCER: A CLINICAL CASE

Shirokorad V.I.

Abstract

The paper describes a clinical case of treatment and follow-up in a prostate cancer patient with very unfavorable baseline prognosis, bone metastases, and good clinical outcome.

Cancer Urology. 2013;9(3):96-104
pages 96-104 views

OBITUARY

ПАМЯТИ АЛЕКСЕЯ ВЛАДИМИРОВИЧА ЛЮЛЬКО

.

Abstract

Памяти Алексея Владимировича Люлько.

Cancer Urology. 2013;9(3):105
pages 105 views

ПАМЯТИ НИКОЛАЯ АЛЕКСЕЕВИЧА ЛОПАТКИНА

.

Abstract

Памяти Николая Алексеевича Лопаткина.

Cancer Urology. 2013;9(3):106
pages 106 views

LECTURE

VARIANTS OF THE INFERIOR VENA CAVA AND ITS TRIBUTARIES: THE CLASSIFICATION, EMBRYOGENESIS, CT IMAGING AND CLINICAL SIGNIFICANCE IN PARA-AORTIC LYMPHADENECTOMY

Mukhtarulina S.V., Kaprin A.D., Astashov V.L., Aseeva I.A.

Abstract

Defect of the embryogenesis of the three paired cardinal veins and their anastomoses leads to the formation of the inferior vena cava abnormalities. Congenital anomalies of the inferior vena cava (IVC) and its tributaries are usually asymptomatic. The computed tomographic (CT) imaging with intravenously administered contrast material is used for identification of the vascular structures and abnormalities. Knowledge of the anomalies of the vessels help the surgeons to avoid the development of complications by the para-aortic lymph node dissection in patients with neoplasm’s of the testis, kidney, and female genital tract. This article reviews the classification, embryogenesis, anatomy, CT imaging and clinical significance in para-aortic lymphadenectomy of the variants of the IVC and its tributaries.

Cancer Urology. 2013;9(3):10-16
pages 10-16 views